doi: 10.3390/nu15224787 67 DollSPronethBTyurinaYYPanziliusEKobayashiSIngoldIet al
Manufacturers are actually not benefitting from [increase in price] in the case of insulin - net prices have consistently fallen YoY for the major branded insulin products Recent initiatives to cap OOP insulin cost & launch branded generics are the right thing to do . Significant variability in insulin cost that patients pay often stems from inadequate or no insurance coverage. This is another area where sensible legislation should be encouraged to re-align incentives & end this cycle of artificial price hiking to enrich middlemen. From the primer linked above : Between 2003 and 2016, the list price for a vial of NovoLog, a popular insulin analog, increased by 310 percent, after adjusting for economy wide inflation
Retains the C-terminal lipolytic domain of HGH without the growth-promoting IGF-1 elevation
Khatib AM, Siegfried G, Prat A, Luis J, Chrtien M, Metrakos P, et al
Because liposomal glutathione is a slightly more expensive option, short courses of its supplementation are utilized, followed by NAC and Vitamin C
